Ophthalmology

surgical specialties

The week's innovation in ophthalmology, published every Sunday for the week before: new technology, AI tools, devices, FDA decisions on new technology and new ways of delivering care, every item linked to its sources.

FDA adds NAION warning to all GLP-1 drugs; optic neuritis often heralds CNS inflammatory disease

A phoropter hanging from a short arm, its wide housing set with rows of small blank dials around two round lens openings.

The Food and Drug Administration (FDA) required all GLP-1 receptor agonist labels to warn of non-arteritic anterior ischemic optic neuropathy (NAION) and told clinicians to refer suspected cases promptly to an ophthalmologist. A 601-patient multicenter cohort found that first-episode optic neuritis was often the start of broader central nervous system inflammatory disease.

  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) said on Nov. 9 that it is requiring all GLP-1 receptor agonist (GLP-1 RA) labels to add the risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions. A meta-analysis of 126 randomized trials found 6.4 cases per 100,000 person-years with GLP-1 RAs versus 3.8 with placebo or other glucose-lowering drugs. In an FDA Sentinel cohort, risk was higher than with DPP-4 inhibitors (hazard ratio 1.43, 95% CI 1.02 to 2.01) but not significantly higher than with SGLT-2 inhibitors. The FDA told clinicians to refer suspected NAION promptly to an ophthalmologist.
    Sources: FDA, NeurologyLive
  • Research Nov 12, 2026
    A multicenter retrospective cohort study published online in Ophthalmology on Nov. 12 followed 601 consecutive patients with first-episode optic neuritis for a median of two years. Overall, 166 (27.6%) had at least one central nervous system inflammatory event beyond the initial optic neuritis, most often recurrent optic neuritis (58.8%), followed by encephalitis (22.9%) and myelitis (18.3%). At last follow-up, 222 patients (36.9%) had single isolated optic neuritis, 134 (22.3%) myelin oligodendrocyte glycoprotein antibody-associated disease, 125 (20.8%) neuromyelitis optica spectrum disorder and 77 (12.8%) multiple sclerosis.

Latest news

Tagged ophthalmology, from the daily briefing

  1. Atropine 0.04% slowed myopia progression more than 0.01% or 0.02% in 264 children with intermittent exotropia
  2. Trial of 750 adults compares amniotic membrane, conjunctival autograft and mitomycin C to prevent pterygium recurrence
  3. Two public glaucoma datasets used to validate AI share at least 1,031 identical eye scans, inflating reported accuracy

See all the latest news

Earlier weeks

The weekly podcast

Each Sunday's ophthalmology innovation roundup as a short audio briefing, read by AI voices. Play any episode here, or follow the show in any podcast app.

In any podcast app, add the feed: https://feeds.transistor.fm/physician-in-the-loop-ophthalmology